Investigating how beta-catenin signaling affects HIV-1 latency
Official title: Role of canonical and non-canonical beta-catenin signaling in HIV-1 latency
Funded at American University · NIH-10871495 · Data updated 2026-11-12
This study is looking into how a specific protein called beta-catenin affects the hidden HIV in immune cells, with the goal of finding new ways to help treat HIV and make it easier to manage.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | American University NIH-funded |
| Lab location | 1 site (Washington, UNITED STATES) |
| Project start | August 23, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $289,015 |
| NIH project number | 7R15AI172610-02 |
| Project ID | NIH-10871495 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who have developed latency and are currently on antiretroviral therapy.
✕Less likely to help
Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms behind HIV-1 latency, which is a major barrier to curing HIV. It aims to explore the role of beta-catenin signaling in regulating the dormant HIV reservoir within immune cells. By identifying new pharmaceutical targets that can influence HIV latency and immune response, the study seeks to develop more effective treatments. The research will utilize various laboratory techniques to analyze how beta-catenin interacts with other proteins involved in HIV latency.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively reduce the HIV reservoir and potentially contribute to a functional cure for HIV.
How similar studies have gone: While the approach of targeting beta-catenin signaling in HIV latency is relatively novel, previous studies have shown promise in exploring latency reversal agents, indicating potential for success.
Where this research is happening
-
American University
Washington, United States Active
Researchers
- Principal investigator: Izumi, Taisuke — American University
- Study coordinator: Izumi, Taisuke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.